Top Healthcare Stocks
Healthcare stocks are finishing the week with small declines
with the NYSE Healthcare Sector Index falling about 0.1% and shares
of healthcare companies in the S&P 500 sliding about 0.2% as a
In company news, NPS Pharmaceuticals Inc. (
) is up more than 24% at $22.48 a share, easing from its new
52-week high of $23.09 after late yesterday projecting global sales
of between $25 million to $30 million for its Gattex/Revestive
medication during FY13.
The so-called orphan drug - marketed as Gattex in the U.S. and
Revestive in E.U. countries - currently is being used by 141
individuals with Short Bowel Syndrome, a potentially
life-threatening disorder when more than two-thirds of a patient's
small intestines are removed. NPSP is expecting that number will
grow, with between 275 to 325 patients receiving the drug therapy
by the end of the year.
Q2 sales of the drug totaled $4.8 million. Overall revenue for
the quarter rose 28% year over year to $36.5 million, topping
analyst estimates by $4.5 million.
Less positive was NPSP swinging to a Q2 net loss of $0.13 per
share from an $0.08 profit last year. Analysts, on average, had
been expecting a $0.05 per share loss for the company in Q2.
In other sector news,
(+) AMED, KKR Asset Management acquires 8.5% stake, purchasing
2.75 million shares for $31.75 million since June, according to
U.S. Securities and Exchange Commission records.
(-) DNDN, Reports Q2 net loss of $0.45 per share, missing the
analyst consensus by $0.04. Revenue falls 8.3% year over year to
$73.29 mln, trailing the Street view by $1.3 mln.
Copyright (C) 2014 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.